Navigation Links
GeoVax to Exhibit at the 2009 BIO International Convention
Date:5/11/2009

Dr. Harriet Robinson to Host HIV Vaccine Panel Discussion

ATLANTA, May 11 /PRNewswire-FirstCall/ --

    WHAT:    GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based,
             publicly traded biopharmaceutical company developing human
             vaccines for diseases caused by HIV-1 (Human Immunodeficiency
             Virus) and other infectious agents to share their strategy for
             the future and plans to expand preventative trials, currently in
             Phase 2a, to proof-of-concept trials in 'at risk' humans and
             move therapeutic trials from non-human primate models to HIV-1
             virus infected individuals.

             Dr. Harriet Robinson to moderate "HIV/AIDS Vaccines: Preventative
             and Therapeutic Approaches to a Global Pandemic"

    WHERE:   2009 BIO International Convention
             Georgia Pavilion (Booth #2817)
             Georgia World Congress Center
             Atlanta, GA

    WHEN:    May 18-21, 2009
             "HIV/AIDS Vaccines: Preventative and Therapeutic Approaches to a
             Global Pandemic" Thursday, May 21, 10-11 a.m., Room B309

    WHO:     Robert McNally, Ph.D., chief executive officer and president
             Mark Reynolds, chief financial officer
             Harriet Robinson, PhD, vice president of research and development
             and developer of the GeoVax vaccine

    WHY:     HIV Vaccine Awareness Day coincides with the opening of the
             conference on May 18, and Sir Elton John delivering a keynote
             address to include how biotechnology is influencing treatment and
             prevention of the diseases.  GeoVax is looking forward to sharing
             with interested partners, investors and media its progress in
             clinical trials during the last six months and its strategy for
             the future.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. GeoVax Labs, Inc. Announces First Quarter Financial Results
2. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
3. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
4. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
5. GeoVax to Present at the BIO CEO & Investor Conference 2009
6. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Presents Data at AIDS Vaccine 2008 Conference
9. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
10. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
11. GeoVax Further Strengthens Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):